This profile is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any compound.
What Is LL-37?
LL-37 is a 37-amino acid cationic peptide derived from the C-terminal region of hCAP18 (human cationic antimicrobial protein 18), the sole member of the cathelicidin family expressed in humans. The name "LL-37" refers to the peptide beginning with two leucine residues (LL) and being 37 amino acids in length. It is produced primarily by neutrophils, epithelial cells, monocytes, and macrophages in response to microbial invasion, inflammation, and tissue injury — functioning as a rapid first-responder of the innate immune system.
Unlike traditional antibiotics that target specific bacterial pathways and are susceptible to resistance development, LL-37 kills bacteria through physical disruption of their cell membranes using an electrostatic charge-based mechanism. This makes it broadly effective across gram-positive and gram-negative bacteria, many fungi, and certain enveloped viruses. Critically, LL-37 retains activity against antibiotic-resistant bacteria including MRSA and drug-resistant Pseudomonas — a property that has made it a focus of intense pharmaceutical research as the antibiotic resistance crisis deepens.
Beyond antimicrobial activity, LL-37 plays important regulatory roles in wound healing, immune cell recruitment, and the resolution of inflammation. Deficiencies in LL-37 expression have been linked to increased susceptibility to skin infections in atopic dermatitis patients and to impaired wound healing in diabetic ulcer models. Conversely, excess LL-37 in certain contexts (such as psoriasis and autoimmune conditions) can drive excessive inflammation. This dual nature — protective at normal levels, potentially pro-inflammatory when dysregulated — is central to understanding LL-37's use as a research peptide.
How It Works
LL-37's antimicrobial mechanism relies on its amphipathic alpha-helical structure, which allows it to interact with negatively charged bacterial cell membranes. The positively charged (cationic) face of the helix is attracted to the negatively charged phospholipid heads of bacterial membranes, while the hydrophobic face inserts into the lipid bilayer. This disrupts membrane integrity through pore formation, carpet-model lysis, or detergent-like solubilization — all resulting in bacterial cell death. Mammalian cell membranes, which contain more neutral phospholipids (phosphatidylcholine) and cholesterol, are less susceptible to this mechanism, providing selectivity for bacteria over host cells.
LL-37's immune modulation occurs through its interactions with Toll-like receptor 4 (TLR4) signaling. It can both activate and suppress TLR4 responses depending on context — at low concentrations in infection, it amplifies immune cell activation and cytokine production to combat pathogens; at higher concentrations or in the context of resolving inflammation, it can suppress TLR4-mediated inflammatory signaling to prevent excessive tissue damage. This context-dependent bidirectional modulation is unusual among innate immune peptides and reflects LL-37's role as a sophisticated regulator rather than a simple on/off switch.
In wound healing, LL-37 promotes the migration of keratinocytes, endothelial cells, and fibroblasts to injury sites, stimulates angiogenesis via VEGF upregulation, and recruits professional immune cells (neutrophils, macrophages) through chemotactic signaling. It also directly disrupts bacterial biofilms — aggregated communities of bacteria enclosed in a protective matrix that are highly resistant to conventional antibiotics — by destabilizing the biofilm structure and increasing antibiotic penetration.
Key Benefits Discussed in Research
Dosing Reference (Educational Only)
LL-37 is classified as Advanced due to its potent immune-modulating activity and the importance of physician oversight. All dosing information is educational only.
| Parameter | Common Research Range | Notes |
|---|---|---|
| Dose | 1–2 mg/day | Lower end of range for immune modulation; higher for acute infection research contexts |
| Cycle Length | 4–6 weeks | Extended use should be monitored; not typically used as an indefinite daily compound |
| Route | SubQ injection | Oral route not appropriate — LL-37 is degraded in the GI tract |
| Frequency | Once daily | Some protocols use every-other-day dosing to reduce local injection site reactions |
| Reconstitution | Bacteriostatic water or sterile saline | Standard peptide reconstitution; refrigerate after mixing; use within 30 days |
| Monitoring | Inflammatory markers recommended | Due to immune-modulating activity, CRP and CBC monitoring is advisable with a physician |
Want the Full LL-37 Protocol?
Join SDBioHack and access community-validated protocols, sourcing checklists, and expert Q&A.
Side Effects & Safety Profile
LL-37 carries a more complex risk profile than most peptides discussed in biohacking communities, which is why it is classified as Advanced. While physiological LL-37 is a normal component of human innate immunity, exogenous administration at research doses can provoke dose-dependent local and systemic reactions. Injection site reactions including redness, swelling, and warmth are common, reflecting LL-37's potent chemotactic activity on local immune cells. Systemic flu-like symptoms, fatigue, and transient elevation of inflammatory markers have been reported, particularly during initial dosing.
A critical consideration is LL-37's role in autoimmune conditions. Elevated LL-37 levels are found in psoriatic plaques, lupus, and other autoimmune conditions, where it appears to contribute to aberrant immune activation by presenting self-nucleic acids to intracellular pattern recognition receptors. Exogenous LL-37 in individuals with these conditions or genetic predispositions could theoretically worsen autoimmune activity. Research context and physician oversight are especially important for individuals with personal or family histories of autoimmune disease.
- Autoimmune conditions (psoriasis, lupus, rheumatoid arthritis): LL-37 may exacerbate disease activity — use with caution or avoid.
- Active inflammatory conditions: high-dose LL-37 can be pro-inflammatory in excess; monitor inflammatory markers.
- Pregnancy and breastfeeding: avoid; insufficient safety data.
- Renal or hepatic impairment: use with caution and physician supervision.
- Do not combine with immunosuppressants without specialist guidance — interactions are poorly characterized.
Common Stacks & Pairings
LL-37 is primarily used in immune-focused protocols rather than general performance or healing stacks. In the context of chronic infection or impaired immune function, it is sometimes paired with Thymosin Alpha-1 (another immune-modulating peptide that promotes T-cell maturation and antiviral activity) to create a comprehensive immune enhancement protocol. For wound-healing applications, LL-37 may be combined with BPC-157 to address both the antimicrobial environment (LL-37) and structural tissue repair (BPC-157). Given LL-37's advanced classification, these stacks require careful physician oversight.
Frequently Asked Questions
Natural production of LL-37 is tightly regulated by the immune system — it is released locally and transiently in response to specific triggers, and its concentration is carefully calibrated by enzymatic processing of the hCAP18 precursor. Exogenous administration bypasses these regulatory controls, delivering a fixed dose systemically. At research doses, the concentrations achieved may be higher or more sustained than physiological levels, activating immune pathways in ways the body's feedback mechanisms cannot fully regulate. The potential to exacerbate autoimmune conditions and provoke systemic inflammatory reactions warrants an Advanced classification and physician oversight.
LL-37 is not a replacement for antibiotics and should not be used as one — particularly for serious or systemic bacterial infections where proven antibiotic therapy is the standard of care. Its research value lies in its complementary mechanisms: membrane-disruption-based killing (not subject to traditional resistance pathways), biofilm disruption, and immune potentiation. Some researchers see future potential for LL-37-derived peptides as adjuncts to antibiotics for resistant infections, but this remains investigational. Self-treating infections with LL-37 instead of appropriate medical care poses significant risk.
Yes, several studies have investigated LL-37's activity against SARS-CoV-2 and influenza viruses in vitro. LL-37 has demonstrated the ability to disrupt the lipid envelope of these viruses and reduce viral entry into host cells in laboratory settings. Some researchers have proposed that LL-37 deficiency (associated with low vitamin D status, which drives hCAP18/LL-37 expression) may partly explain differential COVID-19 susceptibility. However, in vitro findings do not directly translate to clinical efficacy, and no human trials of exogenous LL-37 for respiratory viral infection have been completed to date.
This is one of the most established connections in LL-37 biology. Vitamin D (specifically its active form, 1,25-dihydroxyvitamin D3) directly upregulates the transcription of the CAMP gene, which encodes hCAP18 — the precursor that is proteolytically processed to yield LL-37. Individuals with vitamin D deficiency consistently show reduced LL-37 levels in skin, lungs, and mucosal surfaces, which correlates with increased susceptibility to infections including tuberculosis. Maintaining optimal vitamin D status is widely considered the most accessible and well-evidenced way to support endogenous LL-37 levels.
Vandamme D, et al. "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cellular Immunology. 2012;280(1):22–35.
Doss M, et al. "The role of defensins in lung biology and therapy." American Journal of Respiratory and Critical Care Medicine. 2010;181:1133–1135.
Heilborn JD, et al. "The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds." Journal of Investigative Dermatology. 2003;120(3):379–389.
Wang G. "Human Antimicrobial Peptides and Proteins." Pharmaceuticals. 2014;7(5):545–594.
Tripathi S, et al. "Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses." PLoS ONE. 2015;10(4):e0124706.